Skip to main content
OpenTrials

Clinical trial condition

Refractory Solid Tumors

Explore clinical trials studying Refractory Solid Tumors. Study availability and eligibility vary by location and protocol.

26 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Refractory Solid Tumors trial results

Recruiting

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

NCT06721689

Conditions
Disease Attributes, Myosarcoma, Neoplasms, +22 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Boston Children's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Recruiting

KSH01-TCRT Solid Tumors

NCT05539833

Conditions
Refractory Solid Tumors, Relapsed Solid Tumors, TCR-T Cells
Locations
  • The first affiliated hospital of Guang Xi medical university Nanning, Guangxi, China
View Trial Details
Completed

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

NCT02512926

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Stanford University School of Medicine and Stanford Cancer Institute Palo Alto, California, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)

NCT03247309

Conditions
Cancer, Neoplasms, Recurrent Solid Tumors, +2 more
Locations
  • University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States
  • University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • Universitätsklinikum Bonn, Venusberg-Campus 1 Bonn, North Rhine-Westphalia, Germany
  • Universitätsklinikum Carl Gustav Carus, Fetscherstr. 74 Dresden, Saxony, Germany
View Trial Details
Completed

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

NCT02383368

Conditions
Advanced Cancer, Hemic and Lymphatic Diseases, Immune System Diseases, +7 more
Locations
  • Site US10001 New Haven, Connecticut, United States
  • Site US10004 Chicago, Illinois, United States
  • Site US10002 Rochester, Minnesota, United States
  • Site US10003 Houston, Texas, United States
View Trial Details

Related conditions